Even when lower concentrations of inhibitors were used we still did not find a significant difference between control and PD patient cells however, it may be prudent to perform IC50 curves with actual clinical trial drugs once these have been established and a better idea of the therapeutic window of LRRK2 drugs is known. Here, LRRK2 is linked to Parkinson disease.